Archive for the ‘Gene Therapy Research’ Category

How Alternative Medicine Has Infiltrated U.S. Medical Schools - Steve Salzberg
Presented by the National Capital Area Skeptics - http://www.ncas.org. Alternative medicine has become very popular over the past two decades, thanks to relentless ...

By: NCASVideo

Read more here:
How Alternative Medicine Has Infiltrated U.S. Medical Schools - Steve Salzberg - Video

Minecraft-MOD Advanced Genetics(Genetica avanzada)
Hola amigos de youtube espero que esten muy bien! 😀 Y pues bueno esta ves les traigo un nuevo mod Genetica avanzada (en espaol) Aqui el link de descarga de...

By: Sebpper Torres

Link:
Minecraft-MOD Advanced Genetics(Genetica avanzada) - Video

Genetics Inheritance
Stop-motion animation demonstrating the genetics of meiosis and inheritance, made by group B4 from bridging course class of 2014.

By: FYB Sydney

Read the original here:
Genetics & Inheritance - Video

The Angus Report, Feb. 10, 2014: Building Better Genetics
Cattlemen like Texas Angus breeder Jimmy Goode rely on DNA information from the Zoetis HD 50K test and genomic-enhanced EPDs to make the best possible select...

By: Angus TV

Read this article:
The Angus Report, Feb. 10, 2014: Building Better Genetics - Video

Talent vs Training
Which is more important - genetics or hard work? DAILY EPISODES, answering your burning questions. Watch 5 episodes before anybody else: http://bit.ly/1n5llR...

By: AsapSCIENCE

See the article here:
Talent vs Training - Video

Attack Of The B-Team - Episode 12 - Advanced Genetics
A brand new Mod pack from the Fantastic team over at Technic! Attack Of The B-Team This new pack is a large modpack with big ores, and a mad science theme! N...

By: Gaming On Caffeine

See the original post:
Attack Of The B-Team - Episode 12 - Advanced Genetics - Video

Advanced Genetics 1.4/ MC1.6.4 - Gene Removal
Minecraft 1.6.4 Part 3 of Advanced Genetics tutorial in which i show you how to remove an unwanted gene from your own DNA. Please leave a like if these video...

By: Corerupt83

Read more:
Advanced Genetics 1.4/ MC1.6.4 - Gene Removal - Video

Are Genetics Important For Bodybuilding?
Get Instant Access To My Complete, No B.S, Step-By-Step Muscle Building Fat Loss Programs: http://www.BodyTransformationTruth.com ** Connect With Me ...

By: Sean Nalewanyj

Originally posted here:
Are Genetics Important For Bodybuilding? - Video

Advanced Genetics 1.4/ MC1.6.4 - DNA Cloning and Sampling Mobs
Minecraft 1.6.4 Part 4 of Advanced Genetics tutorial where i show you how to clone your DNA and imprint it onto other mobs which you can then spawn in the wo...

By: Corerupt83

Visit link:
Advanced Genetics 1.4/ MC1.6.4 - DNA Cloning and Sampling Mobs - Video

Advanced Genetics 1.4/ MC1.6.4 - DNA Combining and Analyzing
Minecraft 1.6.4 Part 2 of Advanced Genetics tutorial explaining how to process your ability gene and apply it to your own DNA. Please leave a like if these v...

By: Corerupt83

See the original post:
Advanced Genetics 1.4/ MC1.6.4 - DNA Combining and Analyzing - Video

Reveal Workshop - Character Genetics
The Reveal Workshop is an interactive, engaging, transformative executive group coaching experience that #39;s jam-packed full of strategies and tools that the h...

By: Spirit of Life Church

Continued here:
Reveal Workshop - Character Genetics - Video

Advanced Genetics 1.4/ MC1.6.4 - Power Supply and Gene Creation Basics
Minecraft 1.6.4 Part 1 of Advanced Genetics tutorial explaining what power you can use and the first steps you need to take when using this mod. Please leave...

By: Corerupt83

Read the original here:
Advanced Genetics 1.4/ MC1.6.4 - Power Supply and Gene Creation Basics - Video

Justin Clark #39;s Speech at the Hannah #39;s Hope Ball
The mission of Hannah #39;s Hope Fund (HHF) is to raise funds for a treatment and cure of GAN. Lori and Matt Sames co-founded HHF following the diagnosis of thei...

By: hannahshopefund

Read the original:
Justin Clark's Speech at the Hannah's Hope Ball - Video

Milwaukee, WI (PRWEB) February 13, 2014

The American Society of Gene & Cell Therapy (ASGCT) has announced its 2014 Award Series as part of its 17th Annual Meeting held May 21-24, 2014 at the Marriott Wardman Park in Washington, DC.

ASGCT is honored to recognize Dr. Luigi Naldini from the University Vita-Salute San Raffaele as the recipient of the 2014 Outstanding Achievement Award (OAA). The OAA recognizes an ASGCT Active Member who has achieved a pioneering research success, a specific high impact accomplishment, or a lifetime of significant scientific contributions to the fields of gene and/or cell therapy. Dr. Naldini will present a plenary lecture at the ASGCT 17th Annual Meeting on May 22nd.

Barbara Netter and Edward Netter (deceased) are the recipients of this years Distinguished Service Award. Both will be acknowledged on May 22nd during the ASGCT 17th Annual Meeting for their creation of the Alliance for Cancer Gene Therapy (ACGT). Since its inception in 2001, the foundation has provided $25 million in funding to sponsor medical institutions and researchers dedicated to focusing genetic therapeutics for the treatment of Cancer.

The Outstanding New Investigator Awards are given in recognition of scientists conducting original research in basic science, technology development or clinical translation. Each of the following recipients will present a retrospective of his work on May 23rd during the ASGCT Annual Meeting:

o Brian Brown, PhD - Mt. Sinai School of Medicine o Charles Gersbach, PhD Duke University o Scott Harper, PhD - Ohio State University & Nationwide Children's Hospital o Daniel Powell, PhD - University of Pennsylvania

ASGCT congratulates each of its award winners and is appreciative for their continued contributions to the field of gene and cell therapy.

The American Society of Gene & Cell Therapy (ASGCT) is a professional nonprofit medical and scientific organization dedicated to the understanding, development and application of genetic and cellular therapies and the promotion of professional and public education in the field. For more information on ASGCT, visit its website, http://www.asgct.org.

###

More:
ASGCT Announces 2014 Award Series for Contributions to the Field of Genetic and Cellular Therapy

Total Recovery Lecture Series: Novel Treatments for Joint, Tendon Ligament Pain, Part 3
Dr. David Wang, Harvard trained and Board Certified in Physical Medicine Rehabilitation, is an international leader in the growing field of Regenerative In...

By: KaplanCenter

More here:
Total Recovery Lecture Series: Novel Treatments for Joint, Tendon & Ligament Pain, Part 3 - Video

Cancer researchers led by stem cell scientist Dr. John Dick have discovered a pre-leukemic stem cell that may be the first step in initiating disease and also the culprit that evades therapy and triggers relapse in patients with acute myeloid leukemia (AML).

The research, published online today in Nature is a significant leap in understanding the steps that a normal cell has to go through as it turns into AML, says Dr. Dick, and sets the stage to advance personalized cancer medicine by potentially identifying individuals who might benefit from targeting the pre-leukemic stem cell. AML is an aggressive blood cancer that the new research shows starts in stem cells in the bone marrow. Dr. Dick, a Senior Scientist at Princess Margaret Cancer Centre, University Health Network (UHN), and Professor in the Department of Molecular Genetics, University of Toronto, pioneered the cancer stem cell field by first identifying leukemia stem cells (1994) and colon cancer stem cells (2007).

"Our discovery lays the groundwork to detect and target the pre-leukemic stem cell and thereby potentially stop the disease at a very early stage when it may be more amenable to treatment," says Dr. Dick, who holds a Canada Research Chair in Stem Cell Biology and is also Director of the Cancer Stem Cell Program at the Ontario Institute for Cancer Research (OICR).

"Now we have a potential tool for earlier diagnosis that may allow early intervention before the development of full AML. We can also monitor remission and initiate therapy to target the pre-leukemic stem cell to prevent relapse," he says.

The findings show that in about 25% of AML patients, a mutation in the gene DNMT3a causes pre-leukemic stem cells to develop that function like normal blood stem cells but grow abnormally. These cells survive chemotherapy and can be found in the bone marrow at remission, forming a reservoir of cells that may eventually acquire additional mutations, leading to relapse.

The discovery of pre-leukemic stem cells came out of a large Leukemia Disease Team that Dr. Dick assembled and included oncologists who collected samples for the Princess Margaret Cancer Centre Biobank and genome scientists at the OICR who developed sophisticated targeted sequencing methodology. With this team, it was possible to carry out genomic analysis of more than 100 leukemia genes on many patient samples. The findings also capitalized on data from more than six years of experiments in Dr. Dick's lab involving growing human AML in special mice that do not reject human cells.

"By peering into the black box of how cancer develops during the months and years prior to when it is first diagnosed, we have demonstrated a unique finding. People tend to think relapse after remission means chemotherapy didn't kill all the cancer cells. Our study suggests that in some cases the chemotherapy does, in fact, eradicate AML; what it does not touch are the pre-leukemic stem cells that can trigger another round of AML development and ultimately disease relapse," says Dr. Dick, who anticipates the findings will spawn accelerated drug development to specifically target DNMT3a.

These findings should also provide impetus for researchers to look for pre-cancerous cells in AML patients with other mutations and even in non-blood cancers.

Dr. Dick is also renowned for isolating a human blood stem cell in its purest form (2011) -- as a single stem cell capable of regenerating the entire blood system. He is a Senior Scientist at UHN's McEwen Centre for Regenerative Medicine and co-leader of a Cancer Stem Cell Consortium (CSCC)-funded research project HALT (Highly Active Anti-Leukemia Stem Cell Therapy), which is a partnership between CSCC and the California Institute for Regenerative Medicine.

For more than 20 years, Dr. Dick's research has focused on understanding the cellular processes that maintain tumour growth by investigating the complexities and interplay among genetic and non-genetic determinants of cancer. His research follows on the original 1961 discovery of the blood stem cell by Princess Margaret Cancer Centre (formerly Ontario Cancer Institute) scientists Dr. James Till and the late Dr. Ernest McCulloch, which formed the basis of all current stem cell research.

The rest is here:
Cancer Researchers Discover Pre-Leukemic Stem Cell at Root of AML, Relapse

Poway, California (PRWEB) February 13, 2014

The leading Regenerative Veterinary Medicine company, Vet-Stem, Inc., and Americas best-loved pet insurer, Petplan, are working together to bring stem cell therapy and other regenerative cell therapies to pets nationwide. Stem cell therapy by Vet-Stem has been available for pets like dogs and cats for the last decade and covered by Petplan since 2010.

Founded in 2003 by Chris and Natasha Ashton, Petplan was recently named to Forbes magazines annual ranking of Americas Most Promising Companies for the second year in a row, and is rated one of the top pet insurance companies by Consumer Advocate and Canine Journal. Petplan proudly offers life-long coverage for hereditary and chronic conditions as well as alternative treatments, like stem cell therapy, as standard.

Our core value is that pets come first, and that starts with our comprehensive plans. So, were excited to see so many of our policyholders start to take advantage of cutting-edge treatments like Vet-Stem Regenerative Cell Therapy. Our team thrives on being able to provide coverage for the best and most up-to-date treatment modalities for the pets in our Petplan family, so hearing great stories about stem cell therapy from our policyholders is a real boost for us! - Dr. Jules Benson, Vice President of Veterinary Services at Petplan

Current uses of stem cell therapy are treating the pain and inflammation from arthritis and to repair orthopedic injuries. According to veterinarians, greater than 80% of dogs showed an improved quality of life after stem cell therapy. At 90 days post-treatment, more than 33% of dogs discontinued use of non-steroidal anti-inflammatory drugs (NSAIDs) completely, with an additional 28% decreasing their usage.

I started Vet-Stem in order to help horses with career-ending injuries to their tendons and ligaments, but so many more animals have been saved from a life of pain or even from euthanasia. I feel privileged and excited to be a part of this therapy that has changed how veterinary medicine is practiced, as well as contributing to changes in human medicine, - Robert Harman, DVM, CEO, Vet-Stem, Inc.

About Vet-Stem, Inc. Vet-Stem, Inc. was formed in 2002 to bring regenerative medicine to the veterinary profession. The privately held company is working to develop therapies in veterinary medicine that apply regenerative technologies while utilizing the natural healing properties inherent in all animals. As the first company in the United States to provide an adipose-derived stem cell service to veterinarians for their patients, Vet-Stem, Inc. pioneered the use of regenerative stem cells in veterinary medicine. The company holds exclusive licenses to over 50 patents including world-wide veterinary rights for use of adipose derived stem cells. In the last decade over 10,000 animals have been treated using Vet-Stem, Inc.s services, and Vet-Stem is actively investigating stem cell therapy for immune-mediated and inflammatory disease, as well as organ disease and failure. For more on Vet-Stem, Inc. and Veterinary Regenerative Medicine visit http://www.vet-stem.com or call 858-748-2004.

Read more:
Vet-Stem, Inc. and Petplan Work Together in the New Year to Bring Regenerative Cell Therapies to Pets

TUESDAY, Feb. 11, 2014 (HealthDay News) -- Predicting whether early stage breast cancer will become invasive and lethal remains a challenge for doctors. But new research suggests that a panel of 55 genes might help guide medical odds-makers.

Women who had genetic alterations in this panel were less likely to survive breast cancer over nearly two decades of follow-up than those without any changes, said study researcher Susette Mueller, professor emeritus of oncology at Georgetown University's Lombardi Comprehensive Cancer Center in Washington, D.C.

"If people had changes in any of the 55 genes, they had worse outcomes," she said.

Researchers studying this panel focused on the loss of a powerful tumor suppressor gene known as SYK. When a copy of SYK is lost, 51 other genes are directly affected. This leads to genetic disruption, according to the authors of the study, published online Feb. 11 in PLOS ONE.

The gene screen is far from ready for use in everyday practice, Mueller noted. But it's hoped that more research will show it's a reliable tool, one that might guide doctors making treatment decisions.

"When women have ductal carcinoma in situ (DCIS), it's carcinoma but not invasive," Mueller said. "A small number of them go on to have invasive cancer."

But there is no accurate way to determine which ones will progress and which won't.

How abnormalities in genes might trigger a cancer, predict its progression and help determine the best treatment is the subject of numerous investigations.

For several years, experts have recognized SYK as an inhibitor of breast cancer cell growth and spread. SYK can be lost when a gene is "turned off," Mueller said, or when genetic instability occurs because pieces of DNA are missing, for instance.

In the current study, funded by Georgetown Lombardi and the U.S. Public Health Service, Mueller examined tissue samples from 19 women diagnosed with breast cancer. Eight of the women had ductal carcinoma in situ -- noninvasive cancer, she said. The others also had some cancer in adjacent tissue.

Continued here:
Gene Exam Might Predict Breast Cancer Progression - US News

Houston, Texas (PRWEB) February 12, 2014

Gene by Gene, Ltd., a Houston-based genetic testing company for health and ancestry research, announced today that their genetic testing laboratory is now CAP accredited. The accreditation was based on a recent on-site visit by CAP inspectors and a detailed review of staff qualifications, facilities, laboratory records, protocols and quality control procedures.

Gene by Gene joins an elite group of laboratories worldwide that meet the highest standards of care and quality control. The U.S. federal government recognizes the CAP accreditation program as being equal-to or more-stringent-than the governments own inspection program.

Gene by Gene has offered genetic testing since 2000 and the accreditation of our laboratory by the College of American Pathologists marks an important milestone in our mission to deliver state-of-the-art genetic testing to consumers, researchers, and physicians, said Max Blankfeld, Chief Operating Officer at Gene by Gene, Ltd.

About Gene by Gene, Ltd. Founded in 2000, Gene By Gene, Ltd. (http://www.genebygene.com) is a CAP-accredited and CLIA-registered genetic testing company that serves consumers, researchers, and physicians. Gene by Gene offers a wide range of regulated clinical diagnostic tests, as well as research use only (RUO) tests. The Family Tree DNA division (http://www.familytreeDNA.com) of Gene by Gene is a pioneer and leader in DNA testing for genealogy and ancestry. The company operates the largest genetic genealogy database in the world and has provided more than 5 million discrete genetic tests. Gene by Gene is privately held and headquartered in Houston, Texas.

About the College of American Pathologists The College of American Pathologists (CAP), celebrating 50 years as the gold standard in laboratory accreditation, is a medical society that serves more than 18,000 physician members and the global laboratory community. It is the worlds largest association composed exclusively of board-certified pathologists and is the worldwide leader in laboratory quality assurance. The College advocates accountable, high-quality, and cost-effective patient care.

The rest is here:
Gene by Gene Receives Accreditation from the College of American Pathologists

Genetic Engineering Maximum Ride Style
Abigail Rasch #39;s "Science in Fiction" Video Contest submission ( can also be viewed here: https://www.wevideo.com/view/151007082)

By: Kavli "Science in Fiction" Video Channel

Visit link:
Genetic Engineering Maximum Ride Style - Video

Feature Article of Thursday, 13 February 2014

Columnist: Agorsor, Yafetto, Otwe, Galyuon

Israel D. K. Agorsor, Levi Yafetto, Emmanuel P. Otwe and Isaac K. A. Galyuon

1. Introduction

At the turn of the last decade, Ghana signaled its intention to adopt plant genetic engineering as part of the efforts towards modernizing its agriculture when it established the National Biosafety Committee. This committee would, among others, activate the processes for the formulation of a Biosafety Bill. In 2011, a draft Biosafety Bill was passed into law by Ghanas Parliament, and is known as Biosafety Act 2011 or Act 831. Genetic engineering techniques enable scientists to modify the genetic make-up of an organism, otherwise known as its genome, by inserting into the genome pieces of deoxyribonucleic acid (DNA) ? the genetic material ? that condition specific desirable traits from other organisms. These modifications result in what are known as genetically modified organisms (GMOs) or transgenic organisms (transgenics).

To say that the debates on GMOs are, perhaps, the fiercest of all debates that have ever engulfed any human endeavour and, for that matter, any scientific discipline in living memory may be an understatement. Why the GMO wars have been so fiercely fought is clear only to the extent that people and cultures have significant emotional attachment to food and food products, and thus anything that appears an aberration to these would always be fiercely resisted. However, the evidence, as we have it, is that these debates have at times gone beyond the science, and have assumed moral and speculative dimensions. The result is that quite often, moral questions are also asked to proponents of genetic engineering, questions whose answers may not be readily available.

Some of these moral questions include: Are scientists now playing God? Why do scientists interfere in nature and the natural order? Speculative ones include the myriad of diseases, such as cancer, heart diseases, diabetes and fibroid, that genetically modified (GM) food causes. Of course we are aware of some published reports which suggest GM foods could have adverse effects on human and animal health. But we are also aware that some of these reports have either been challenged or retracted from the scientific journals in which they were published after follow-up studies showed that the experiments leading to those conclusions were flawed. You may read, for example, Sralini affair at http://en.wikipedia.org/wiki/S%C3%A9ralini_affair, as well as the widely-referenced Pusztai study which although hailed by some scientists, has been challenged by others including the UK Royal Society. See the Pusztai affair at http://en.wikipedia.org/wiki/Pusztai_affair.

We have noticed, too, that in an opinion piece that appeared in the Daily Graphic of Monday, December 23, 2013, and titled GM Foods: Mass genocide, studies by Australian scientist Judy Carman and her colleague Jack Heinemann have been cited as evidence of health risks of GMOs. In fact, Carman and co-authors studies have been disputed. Many scientists, including the food regulator for Australia/New Zealand known as Food Standards Australia and New Zealand (FSANZ) have rejected Carman and colleagues claim that GM foods have health risks as reported in one study. See FSANZs response to Carman and colleagues claims at http://www.foodstandards.gov.au/consumer/gmfood/Pages/Response-to-Dr-Carman's-study.aspx. Basically, the charge is that it was flawed science that led to their claims.

For an example of a publication that discusses the health implications of GM foods, see the article (not an original research paper, but a review article) Health risks of genetically modified foods by Dona and Arvanitoyannis published in the journal Critical Reviews in Food Science and Nutrition in 2009 (Crit Rev Food Sci Nutr 49(2): 164-175) at http://www.ncbi.nlm.nih.gov/pubmed/18989835 (click on View full text). For a challenge to the views expressed in Dona and Arvanitoyannis, see the article Response to Health risks of genetically modified foods by Craig Rickard in the same journal at http://www.tandfonline.com/doi/full/10.1080/10408390903467787#tabModule.

Unfortunately, the independence of the authors of some of the pro- and anti-GMO articles and research papers have been questioned at times; the authors have been accused of doing the bidding of either biotechnology giants or anti-GMO movements because they have been receiving, allegedly, research funding from these groups. These accusations have also added to the complexity of the GMO debates.

Read more:
Ghanas GMO debates: beyond the sticking points (1)

PARIS, Feb 13 (BERNAMA-NNN-PRENSA LATINA) -- French company Abivax and the Centre for Genetic Engineering and Biotechnology (CIGB) in Cuba announced an agreement here Wednesday to partner in the development and commercialisation of vaccines with one against the Hepatitis B virus.

The CIGB, Cuba's leading biotechnology institution, has more than 50 research-development projects, while Abivax, based in Paris, is a product of the merger of the Wittycell, Splicos and Zophis firms. Their objective is to fight infectious diseases and cancer.

"Cuba is known for the excellence of its physicians and the quality of its vaccines. This is a project of international importance to put France foremost in this matter," Philippe Pouletty, president of the Administrative Council of the French firm, said.

Norkis Arteaga, head of Biocubafarma business department, said that the complementary nature of both companies in research and production will allow for the distribution of many products in the future.

Arteaga cited in a statement a licensing agreement between the CIGB and Abivax for the development and commercialisation of the therapeutic vaccine against Hepatitis B.

Cuba will provide the clinical results and capacity, while the French firm financial resources to complete other clinical trials in Europe and Asia along with the experience to register it in these markets and commercialise it later.

-- BERNAMA-NNN-PRENSA LATINA

See more here:
Cuba, France Agree To Develop Hepatitis B Vaccine

by Mark Derewicz

(Medical Xpress)Put yourself in the shoes of a psychiatrist. You just diagnosed a person with schizophrenia, and you can prescribe any number of antipsychotic drugs, all of which can cause serious side effects. You know that older drugs, such as haloperidol, work well, but a third of all schizophrenia patients who take it suffer from Parkinsonian-like symptoms, such as tremors, involuntary spasms, and uncontrollable facial movements. You also know that those side effects are permanent in about half the people who experience them. In other words, you could be prescribed a drug that causes permanent brain damage.

So you consider prescribing a newer drug, such as clozapine, which also helps a large portion of patients. But clozapine causes severe weight gain and diabetes in many people. You check your patient's history. He smokes, as do 90 percent of people diagnosed with schizophrenia. He weighs a lot for his height. Taking clozapine will substantially increase his risk of heart disease, and the drug costs much more than haloperidol. Your patient can't afford it.

Choosing the right drug is difficult, but you have to choose one. Letting the patient go without medication is not an option; untreated schizophrenia is much worse than even the most serious side effects.

What do you do?

You know what you'd like to do: run a blood test to figure out your patient's genetic susceptibility to the permanent side effects of haloperidol. But that genetic screen doesn't exist. In fact, the genetic underpinnings of drug side effects, in general, are not well understood.

Researchers at the UNC School of Medicine are trying to change that.

Two labs headed by statistical geneticist William Valdar, PhD, and psychiatric geneticist Patrick Sullivan, MD, have developed a new statistical model that scientists can use to parse the complex genetics of side effect susceptibility.

In a paper featured in the journal Genetics, their teams describe how they've begun to strip away the mystery behind haloperidol. Their findings represent the first quantitative description of the genetic architecture of haloperidol response.

Genetic smoke screen

Excerpt from:
The genetics of drug tolerance

Researchers at the UNC School of Medicine conducted a comprehensive genetic analysis of invasive bladder cancer tumors to discover that the disease shares genetic similarities with two forms of breast cancer. The finding is significant because a greater understanding of the genetic basis of cancers, such as breast cancers, has in the recent past led to the development of new therapies and diagnostic aids.

Bladder cancer, which is the fourth most common malignancy in men and ninth in women in the United States, claimed more than 15,000 lives last year.

The analysis of 262 bladder cancer tumors, published online in the Proceedings of the National Academy of Sciences, revealed that the invasive form of the disease can be classified into two distinct genetic subtypes -- basal-like and luminal -- which were shown to be highly similar to the basal and luminal subtypes of breast cancer first described by Charles Perou, PhD, the May Goldman Shaw Distinguished Professor of Molecular Oncology at UNC Lineberger.

"It will be particularly interesting to see whether the bladder subtypes, like the breast subtypes, are useful in stratification for therapy," said lead author William Kim, MD, a researcher at the UNC Lineberger Comprehensive Cancer Center and associate professor in the departments of genetics and medicine at UNC.

Mapping genetic signaling pathways of breast cancer subtypes has led to the development of drugs to treat patients and diagnostic aids that help physicians determine the best course of therapy for patients. Because the identified bladder cancer subtypes share many of the same genetic signaling pathways of breast cancer, researchers hope that the identification of the genetic subtypes can lead to similar advances.

"Currently there are no approved targeted therapies for bladder cancer," said lead author Jeffrey Damrauer, graduate student in the Curriculum of Genetics and Molecular Biology at the UNC School of Medicine. "Our hope is that the identification of these subtypes will aid in the discovery of targetable pathways that will advance bladder cancer treatment."

The study also revealed a possible answer to why women diagnosed with bladder cancer have overall poorer outcomes compared to males. Analysis showed that female patients had a significantly higher incidence of the deadlier basal-like tumors. But researchers said that more research is needed before a definite link between the subtype and survival rate can be confirmed.

Dr. Kim's lab has developed a gene map -- BASE47 -- that proved successful as a prognostic aid when applied to the tumor samples in the study. The PAM50 genetic test, a similar genetic map developed in the Perou lab, was recently approved as a clinical diagnostic tool by the FDA.

Story Source:

The above story is based on materials provided by University of North Carolina Health Care. Note: Materials may be edited for content and length.

Read the original post:
Potential route to bladder cancer diagnostics, treatments

Attack Of The B-Team - Episode 6 - Advanced Genetics
Leave a like if you want to see more Attack Of The B-Team! DESCRIPTION Join me as I undertake the most epic quest of evilness, into the new mod pack brought ...

By: WTFG33ks

Read more:
Attack Of The B-Team - Episode 6 - Advanced Genetics - Video